BioCentury | Dec 10, 2020
Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

...are FB-401, which contains three Roseomonas strains, from Forte Biosciences Inc....
BioCentury | Feb 21, 2020
Product Development

Feb. 20 Product Development Quick Takes: Priority Review puts BioMarin on track to score first hemophilia gene therapy approval in U.S.; plus Gilead-CDC, Genfit

...with placebo. Forte to trade on NASDAQ following reverse-merger with Tocagen Inflammatory skin disease company Forte Biosciences Inc....
Items per page:
1 - 2 of 2
BioCentury | Dec 10, 2020
Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

...are FB-401, which contains three Roseomonas strains, from Forte Biosciences Inc....
BioCentury | Feb 21, 2020
Product Development

Feb. 20 Product Development Quick Takes: Priority Review puts BioMarin on track to score first hemophilia gene therapy approval in U.S.; plus Gilead-CDC, Genfit

...with placebo. Forte to trade on NASDAQ following reverse-merger with Tocagen Inflammatory skin disease company Forte Biosciences Inc....
Items per page:
1 - 2 of 2